ClinicalTrials.gg
Active, not recruitingNCT06635850PHocusUpdated Sep 10, 2026

A Study of Mosliciguat in PH-ILD

A Phase 2 interventional study of Mosliciguat and Dry Powder Inhaler in Pulmonary Hypertension, Interstitial Lung Disease and Lung Diseases, sponsored by Pulmovant, Inc.. Active, not recruiting at 85 sites in 20 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Pulmovant, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 397 studies in Hypertension, Pulmonary with a site in United States — 73 open to participants now, 87 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Enrollment
68th of 286
135 · median 30
Started
2024
with 13 others
Phase 2
93 of 397
13 open now
Primary completion
2026-05
later than 14 of 85 live
Registered
354th of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 68th largest by enrollment of the 286 interventional ones that give a count, is one of 14 that started in 2024, is one of 93 in phase 2, reaches primary completion later than 14 of the 85 other live ones, and was the 354th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

73 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Read the detailed description

This study is a randomized, double-blind, placebo-controlled study with an extension.

The study consists of 2 periods: a blinded placebo-controlled period (24 weeks) and an extension (beyond 24 weeks).

Participants will be randomized to receive mosliciguat or placebo in the 24-week double-blind treatment period.

All participants who complete the 24-week double-blind period may continue to participate in the extension period where all participants will receive mosliciguat.

03

Conditions studied

  • Pulmonary Hypertension
  • Interstitial Lung Disease
  • Lung Diseases
  • Vascular Diseases
  • Cardiovascular Diseases
  • Fibrosis

Keywords

  • PH
  • ILD
  • 6 Minute Walk Test
  • mosliciguat
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants willing and able to provide
  • Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include one of the following:

    1. Idiopathic interstitial pneumonia (IIP)
    2. Chronic pneumonitis
    3. ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \< 70% of predicted
  • Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).
  • Ability to perform 6MWT ≥100 meters.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of WHO PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
  • Exacerbation of underlying lung disease requiring augmentation of therapy or emergent hospitalization within 28 days prior to randomization.
  • Initiation of pulmonary rehabilitation within 28 days prior to randomization.
  • Receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
  • History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.
  • Receipt of , or experimental therapy within 42 days OR 5 half-lives prior to randomization.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (actual)

Study arms

  • Active comparator
    Mosliciguat

    Participants will be randomized to receive inhaled mosliciguat or placebo daily for 24 weeks

    Drug: Mosliciguat · Device: Dry Powder Inhaler

  • Placebo comparator
    Matched Placebo

    Participants will be randomized to receive inhaled mosliciguat or placebo daily for 24 weeks

    Device: Dry Powder Inhaler · Drug: Placebo

  • Experimental
    Extension

    After Week 24, all participants may receive mosliciguat through an Extension period

    Drug: Mosliciguat · Device: Dry Powder Inhaler

Interventions

  • Dose level 1, 2, or 3 for inhalation

  • DeviceDry Powder Inhaler

    Dry powder inhaler for mosliciguat or placebo delivery

  • DrugPlacebo

    Matching placebo for inhalation

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)

    PVR evaluated using right heart catheterization (RHC).

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Change from Baseline to Week 16 in Distance Achieved on the Six-Minute Walk Test (6MWT)

    The 6MWT measures the distance a participant is able to walk quickly on a flat, hard surface in a period of 6 minutes.

    Time frame: Baseline, Week 16

  2. Change from Baseline to Week 16 in N-terminal pro-brain natriuretic peptide (NT-proBNP)

    The NT-proBNP serum concentration is a useful biomarker associated with changes in right heart morphology and function. NT-proBNP serum concentration will be assessed to compare the severity of heart failure at Baseline and Week 16.

    Time frame: Baseline, Week 16

07

Study locations

85 sites
  • Clinical Research Site
    Phoenix, Arizona 85012, United States
  • Clinical Research Site
    Los Angeles, California 90024, United States
  • Clinical Research Site
    Sacramento, California 95817, United States
  • Clinical Research Site
    Santa Barbara, California 93105, United States
  • Clinical Research Site
    Torrance, California 90502, United States
  • Clinical Research Site
    Washington D.C., District of Columbia 20037, United States
  • Clinical Research Site
    Celebration, Florida 34746, United States
  • Clinical Research Site
    Chicago, Illinois 60026, United States
  • Clinical Research Site
    Iowa City, Iowa 52242, United States
  • Clinical Research Site
    Kansas City, Kansas 66160, United States
  • Clinical Research Site
    Louisville, Kentucky 40202, United States
  • Clinical Research Site
    Boston, Massachusetts 02111, United States
  • Clinical Research Site
    Boston, Massachusetts 02115, United States
  • Clinical Research Site
    New York, New York 10016, United States
  • Clinical Research Site
    New York, New York 10029, United States
  • Clinical Research Site
    Durham, North Carolina 27710, United States
  • Clinical Research Site
    Greensboro, North Carolina 27403, United States
  • Clinical Research Site
    Cincinnati, Ohio 45267, United States
  • Clinical Research Site
    Bend, Oregon 97701, United States
  • Clinical Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Clinical Research Site
    East Providence, Rhode Island 02915, United States
  • Clinical Research Site
    Charleston, South Carolina 29425, United States
  • Clinical Research Site
    Dallas, Texas 75390, United States
  • Clinical Research Site
    Houston, Texas 77030, United States
  • Clinical Research Site
    Salt Lake City, Utah 84132-0001, United States
  • Clinical Research Site
    Ciudad Autónoma de Buenos Aires, Buenos Aires 1426, Argentina
  • Clinical Research Site
    Santa Fe, S3000EOZ, Argentina
  • Clinical Research Site
    Sydney, New South Wales 2050, Australia
  • Clinical Research Site
    Westmead, New South Wales 2145, Australia
  • Clinical Research Site
    Auchenflower, Queensland 4066, Australia
  • Clinical Research Site
    Brussels, Brussels Capital 1070, Belgium
  • Clinical Research Site
    Leuven, Flanders 3000, Belgium
  • Clinical Research Site
    Porto Alegre, Rio Grande do Sul 90020090, Brazil
  • Clinical Research Site
    Blumenau, Santa Catarina 89010-906, Brazil
  • Clinical Research Site
    São Paulo, 04024-002, Brazil
  • Clinical Research Site
    São Paulo, 05403-904, Brazil
  • Clinical Research Site
    Calgary, Alberta T1Y 6J4, Canada
  • Clinical Research Site
    London, Ontario N6A 5W9, Canada
  • Clinical Research Site
    Toronto, Ontario M5G 2C4, Canada
  • Clinical Research Site
    Prague, Prague 128 08, Czechia
  • Clinical Research Site
    Prague, Prague 140 59, Czechia
  • Clinical Research Site
    Bron, Auvergne-Rhône-Alpes 69677, France
  • Clinical Research Site
    Saint-Priest-en-Jarez, Auvergne-Rhône-Alpes 42270, France
  • Clinical Research Site
    Strasbourg, Bas-Rhin 67091, France
  • Clinical Research Site
    Le Kremlin-Bicêtre, Île-de-France Region 94270, France
  • Clinical Research Site
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • Clinical Research Site
    München, Bavaria 81377, Germany
  • Clinical Research Site
    Dresden, Saxony 01307, Germany
  • Clinical Research Site
    Halle, Saxony-Anhalt 06120, Germany
  • Clinical Research Site
    Genova, Genoa 16132, Italy
  • Clinical Research Site
    Pavia, Lombardy 27100, Italy
  • Clinical Research Site
    Naples, 80131, Italy
  • Clinical Research Site
    Palermo, 90127, Italy
  • Clinical Research Site
    Roma, 00161, Italy
  • Clinical Research Site
    Narashino, Chiba 2758580, Japan
  • Clinical Research Site
    Sapporo, Hokkaido 060-8648, Japan
  • Clinical Research Site
    Kobe, Hyōgo 650-0017, Japan
  • Clinical Research Site
    Yokohama, Kanagawa 236-0051, Japan
  • Clinical Research Site
    Okayama, Okayama-ken 701-1192, Japan
  • Clinical Research Site
    Suita, Osaka 564-8565, Japan
  • Clinical Research Site
    Chiyoda City, Tokyo 102-0071, Japan
  • Clinical Research Site
    Riga, 1002, Latvia
  • Clinical Research Site
    Mexico City, Mexico City 14080, Mexico
  • Clinical Research Site
    Nijmegen, Gelderland 6500 HB, Netherlands
  • Clinical Research Site
    Amsterdam, North Holland 1081 HV, Netherlands
  • Clinical Research Site
    Christchurch, Canterbury 8041, New Zealand
  • Clinical Research Site
    Hamilton, Waikato Region 3240, New Zealand
  • Clinical Research Site
    Poznan, Greater Poland Voivodeship 61 848, Poland
  • Clinical Research Site
    Lodz, Lódzkie 91-347, Poland
  • Clinical Research Site
    Otwock, Masovian Voivodeship 05-400, Poland
  • Clinical Research Site
    Incheon, Incheon Gwang'yeogsi [Inch'on-Kwangyokshi] 21565, South Korea
  • Clinical Research Site
    Dongjak, Seoul Teugbyeolsi [Seoul-T'ukpyolshi] 7061, South Korea
  • Clinical Research Site
    Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi] 06351, South Korea
  • Clinical Research Site
    Seoul, Seoul-Teukbyeolsi 05505, South Korea
  • Clinical Research Site
    Santander, Cantabria 39008, Spain
  • Clinical Research Site
    Marbella, Málaga 29603, Spain
  • Clinical Research Site
    Madrid, 28041, Spain
  • Clinical Research Site
    Toledo, 45007, Spain
  • Clinical Research Site
    Pendik, Istanbul 34899, Turkey (Türkiye)
  • Clinical Research Site
    Bornova, İzmir 35100, Turkey (Türkiye)
  • Clinical Research Site
    Cambridge, England CB2 0AY, United Kingdom
  • Clinical Research Site
    London, England NW3 2QG, United Kingdom
  • Clinical Research Site
    London, England SW3 6NP, United Kingdom
  • Clinical Research Site
    London, England W12 0HS, United Kingdom
  • Clinical Research Site
    Clydebank, Scotland G81 4DY, United Kingdom
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in May 2026, 18 months.

Of 50 phase 2 interventional studies under Hypertension, Pulmonary, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 71. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 10, 2024
StartActual
Oct 29, 2024
Primary completionActual
May 26, 2026
CompletionEst.
Jan 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06635850
Lead sponsor
Pulmovant, Inc.
Responsible party
Sponsor
First posted
Oct 10, 2024
Start date
Oct 29, 2024
Primary completion
May 26, 2026
Completion
Jan 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Ubaldo Martin, MD
study director · Pulmovant, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosliciguat

Start the discussion